CCR Translation for This Article from Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

MLA

Josep Tabernero, et al. CCR Translation for This Article from Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22452234.v1.

APA

Josep Tabernero, José Baselga, Maria Josepa Carreras, Erik A.C. Wiemer, Yoshiharu Mizui, Maja J.A. de Jonge, Adelaida Piera, James P. O’Brien, Herman Burger, Francisco J. Ramos, & Ferry A.L.M. Eskens. (2023). CCR Translation for This Article from Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors. https://doi.org/10.1158/1078-0432.22452234.v1

Chicago

Josep Tabernero, José Baselga, Maria Josepa Carreras, Erik A.C. Wiemer, Yoshiharu Mizui, Maja J.A. de Jonge, Adelaida Piera, et al. 2023. “CCR Translation for This Article from Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors,” March. doi:10.1158/1078-0432.22452234.v1.